UnknownPhase 1/2

Management of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis

50 participantsStarted 2019-01-01

Plain-language summary

The primary goal of this study is to compare well-defined pleural effusion management success outcomes in patients with malignant or paramalignant pleural effusions who were treated with Indwelling pleural catheter insertion compared with those treated with siver nitrate pleurodesis. It is also to demonstrate the effectiveness of silver nitrate pleurodesis. It is also important to evaluate frequent adverse events of silver nitrate pleurodesis in patients with malignant pleural effusion

Who can participate

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Unilateral symptomatic recurrent malignant pleural effusion patients who fulfill the criteria for pleurodesis (i.e. positive pleural biopsy or cytology for malignancy, a Karnofsky index score of more than 60 and life expectancy of more than one year).
✓. Rapidly accumulated undiagnosed pleural effusion .
✓. Age : 30-75 years old.

Exclusion criteria

✕. Transudative pleural effusion.
✕. Exudative pleural effusion due to causes other than malignancy ( i.e. parapnuemonic , post-tuberculous pleural effusion )
✕. Presence of hemorrhagic diathesis ( prothrombin time \<50% and platelet count \<80,000/mm 3 )
✕. Active pleural or systemic infection.
✕. Neoplastic infiltration of the skin at the site of pleural catheter insertion.
✕. Malignant pleural effusion with trapped lung or loculated pleural effusion.
✕. Previous lobectomy or pneumonectomy on the affected side.
✕. Karnofsky index score\> 50.

What they're measuring

Success rate of silver nitrate pleurodesis

Timeframe: One week

Success rate of silver nitrate pleurodesis

Timeframe: One month

Trial details

NCT IDNCT03781908

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-01

Contact for this trial

Khaled Essmat, Master

+201003382727 khaledessmat@outlook.com

View on ClinicalTrials.gov More Pleural Effusion, Malignant trials